Biocardia Inc (BCDA) Stock Price, Quote & News

Company Profile

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. It is also developing an allogeneic cells therapy platform...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 226 0120

Fax: 650 631 3731

Website: www.biocardia.com

Address:

320 Soquel Way, Sunnyvale, United States

Raycloser Mar. 21 at 8:41 PM

$BCDA does anyone think some positive developments will be discussed on Tuesday?

1 · Reply

OfficialStocktwitsUser Mar. 19 at 5:55 PM

$BCDA RSI: 42.47, MACD: 0.0033 Vol: 0.06, MA20: 1.24, MA50: 1.26 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

chris_stocks Mar. 19 at 9:37 AM

$BCDA it shot up to $1.44 at around 5:30. I wonder why

0 · Reply

Raycloser Mar. 17 at 11:29 PM

$BCDA I’d love to see several significant insider buys right around now

1 · Reply

ByBi Mar. 17 at 10:45 PM

$TNXP $GRAL $HSCS $BCDA Agreed. Tnxp long term downtrend reversing seem here. This swing trade heading to low 100's if it does. One of the best 2026 potential out there imo. 👀👀👀

1 · Reply

TheUnmaker Mar. 17 at 8:49 PM

$TNXP If you connect a descending trend line from the top of the candle on 12/17/24 and connect it to the top of the candle on 8/14/25 you will see that it descends down to todays top price. Between $12.80 and $15.45 is a strong demand zone. We are nearing a breakout if this buying zone remains. I want my $59 gap fill. Loading for the long haul on this sleeper! $GRAL $HSCS $BCDA

0 · Reply

canievas Mar. 17 at 2:33 PM

$BCDA target here $50 and she will rest at $25 Buy Now before it’s to late. 🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀 Be patient

0 · Reply

chris_stocks Mar. 17 at 1:33 PM

$BCDA Additional Upcoming Catalysts: They just got good news today, and this stock fell a few cents instead of rising. I swear, nothing really helps this stock. Anyway, below are a few upcoming catalysts that might help: CardiAMP for Ischemic HFrEF, FDA Q-Sub on Approval Pathway, Q1 CardiAMP for Ischemic HFrEF, Japan PMDA Formal Clinical Consultation, Q2 CardiAMP for Chronic Myocardial Ischemia, Oral Presentation at Euro PCR, Q2

0 · Reply

Jusme Mar. 17 at 1:05 PM

$BCDA FDA Helix approval coming soon!

0 · Reply

Denk333 Mar. 16 at 12:20 PM

$BCDA I will keep an eye on this one this week. It has been accumulating and flashing

0 · Reply

BioCardia to Host 2025 Financial Results and Corporate Update Conference Call on March 24, 2026

Feb 10, 2026, 9:15 AM EST - 5 weeks ago

BioCardia Files Pre-Submission for FDA Approval of Helix™ Transendocardial Delivery Catheter for Therapeutic and Diagnostic Agent Delivery to the Heart

Dec 16, 2025, 8:00 AM EST - 3 months ago

BioCardia Cell Therapy for Ischemic Heart Failure to Progress to Formal Clinical Consultation with Japan PMDA

Dec 1, 2025, 8:30 AM EST - 3 months ago

BioCardia to Present at December 2025 CSI Focus Devices in Heart Failure Congress

Nov 24, 2025, 8:15 AM EST - 4 months ago

BioCardia Strengthens Leadership Team with The Addition of Farhan Shahab as Vice President of Quality

Nov 12, 2025, 4:40 PM EST - 4 months ago

BioCardia Reports Third Quarter 2025 Business Highlights and Financial Results

Nov 5, 2025, 7:29 PM EST - 4 months ago

BioCardia to Host Q3 2025 Corporate Update and Financial Results Conference Call on November 12, 2025

Oct 2, 2025, 8:00 AM EDT - 6 months ago

BioCardia Regains Compliance with Nasdaq Listing Requirements

Sep 18, 2025, 9:15 AM EDT - 6 months ago

BioCardia Announces Pricing of Up To $12 Million Public Offering

Sep 18, 2025, 7:00 AM EDT - 6 months ago

BioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Top Line Data of Roll-in Cohort Show Improved Exercise Tolerance and Reduced Angina Episodes at Six-Month Primary Follow-up

Sep 4, 2025, 9:00 AM EDT - 7 months ago

BioCardia CEO Peter Altman to Present at the H. C. Wainwright 27th Annual Global Investment Conference in New York City September 8-10, 2025

Aug 11, 2025, 9:15 AM EDT - 7 months ago

BioCardia Reports Second Quarter 2025 Business Highlights and Financial Results

Aug 6, 2025, 3:18 PM EDT - 8 months ago

BioCardia to Host Q2 2025 Corporate Update and Financial Results Conference Call on August 11, 2025

Aug 4, 2025, 6:00 AM EDT - 8 months ago

BioCardia Provides Update on Timing of Regulatory Activities Seeking FDA Approval and Japan PMDA Approval for CardiAMP® Cell Therapy for Heart Failure and Helix™ Transendocardial Delivery Catheter

May 21, 2025, 8:30 AM EDT - 10 months ago

BioCardia to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21, 2025

May 14, 2025, 4:05 PM EDT - 11 months ago

BioCardia Reports First Quarter 2025 Business Highlights and Financial Results

May 9, 2025, 4:28 PM EDT - 11 months ago

BioCardia to Host Q1 2025 Corporate Update and Financial Results Conference Call on May 14, 2025

Apr 11, 2025, 9:15 AM EDT - 1 year ago

BioCardia Initiates Patient Enrollment at Emory University School of Medicine for Ongoing CardiAMP HF II Pivotal Study

Mar 31, 2025, 1:39 PM EDT - 1 year ago

BioCardia's Conference Call Today, Monday, March 31, 2025 to be Held at 4:30PM EDT Time Today

Mar 26, 2025, 4:30 PM EDT - 1 year ago

BioCardia Reports 2024 Business Highlights and Financial Results

Mar 21, 2025, 8:30 AM EDT - 1 year ago

BioCardia to Host 2024 Financial Results and Corporate Update Conference Call on March 31, 2025

Mar 10, 2025, 9:15 AM EDT - 1 year ago

BioCardia Announces Japanese Patent for Helix™ Biotherapeutic Delivery System

Feb 27, 2025, 9:15 AM EST - 1 year ago

BioCardia Announces Primary Outcome Measures Data Freeze in CardiAMP Heart Failure Trial for Presentation at the American College of Cardiology 2025 Scientific Sessions

Feb 13, 2025, 8:30 AM EST - 1 year ago

BioCardia Reports Completion of Low Dose Cohort Enrollment for CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells to Treat Ischemic Heart Failure of Reduced Ejection Fraction (HFrEF)

Jan 27, 2025, 9:15 AM EST - 1 year ago

BioCardia Announces Late Breaking Clinical Trial Presentation on CardiAMP Heart Failure Trial at the American College of Cardiology 2025 Scientific Sessions

Dec 4, 2024, 8:30 AM EST - 1 year ago

BioCardia Announces Positive Consultation with Japan PMDA on CardiAMP Cell Therapy for Ischemic Heart Failure

Sep 18, 2024, 8:30 AM EDT - 1 year ago

BioCardia Regains Full Compliance with Nasdaq Listing Requirements

Sep 9, 2024, 4:05 PM EDT - 1 year ago

BioCardia Announces Closing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules

Aug 29, 2024, 8:30 AM EDT - 1 year ago

BioCardia Announces FDA Market Clearance of Morph® DNA™ Steerable Introducer Product Family

Aug 21, 2024, 7:00 AM EDT - 1 year ago

FDA Approves CardiAMP® Heart Failure II Protocol Amendment to Use Proprietary Cell Population Analysis Screening to Define Treatment

Aug 13, 2024, 4:30 PM EDT - 1 year ago

BioCardia Reports Second Quarter 2024 Business Highlights and Financial Results

Jul 17, 2024, 7:00 AM EDT - 1 year ago

BioCardia Announces United States Patent Issuance on Morph DNA Multi-Directional Steerable Catheter Transseptal Application

Jun 7, 2024, 7:00 AM EDT - 1 year ago

BioCardia Announces United States Patent Issuance on Intramyocardial Delivery of Cell Aggregates to the Heart Including Minimally Invasive Radial Artery Approach

May 21, 2024, 5:00 PM EDT - 1 year ago

BioCardia Announces Reverse Stock Split

May 14, 2024, 4:02 PM EDT - 2 years ago

BioCardia Reports First Quarter 2024 Business Highlights and Financial Results

May 9, 2024, 7:00 AM EDT - 2 years ago

BioCardia to Host Q1 2024 Financial Results and Corporate Update Conference Call on May 14, 2024

May 1, 2024, 7:00 AM EDT - 2 years ago

BioCardia's CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important Outcomes

Apr 25, 2024, 9:00 AM EDT - 2 years ago

BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort

Mar 27, 2024, 4:00 PM EDT - 2 years ago

BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results

Mar 20, 2024, 7:00 AM EDT - 2 years ago

BioCardia to Host 2023 Financial Results and Corporate Update Conference Call on March 27, 2024

Mar 13, 2024, 7:00 AM EDT - 2 years ago

BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership

Mar 12, 2024, 7:00 AM EDT - 2 years ago

BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study

Mar 4, 2024, 8:00 AM EST - 2 years ago

BioCardia Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure

Feb 8, 2024, 7:00 AM EST - 2 years ago

BioCardia Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDA

Jan 31, 2024, 7:00 AM EST - 2 years ago

BioCardia Announces Two Scientific Abstracts Have Been Accepted at the 2024 Technology and Heart Failure Therapeutics Conference

Jan 3, 2024, 7:00 AM EST - 2 years ago

BioCardia Biotherapeutic Delivery and Morph Access Innovations Business Development Update for Shareholders

Dec 19, 2023, 7:00 AM EST - 2 years ago

BioCardia Doses First Patient in CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells for the Treatment of Ischemic Heart Failure of Reduced Ejection Fraction

Dec 18, 2023, 7:16 AM EST - 2 years ago

BioCardia Announces Expected CardiAMP Heart Failure Japan Approval Timeline Based on Pharmaceutical and Medical Device Agency Consultation Minutes

Nov 29, 2023, 7:00 AM EST - 2 years ago

BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure; Foreign Data Expected to be Sufficient for Product Approval

Nov 16, 2023, 12:56 PM EST - 2 years ago

BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules

Raycloser Mar. 21 at 8:41 PM

$BCDA does anyone think some positive developments will be discussed on Tuesday?

1 · Reply

OfficialStocktwitsUser Mar. 19 at 5:55 PM

0 · Reply

chris_stocks Mar. 19 at 9:37 AM

$BCDA it shot up to $1.44 at around 5:30. I wonder why

0 · Reply

Raycloser Mar. 17 at 11:29 PM

$BCDA I’d love to see several significant insider buys right around now

1 · Reply

ByBi Mar. 17 at 10:45 PM

$TNXP $GRAL $HSCS $BCDA Agreed. Tnxp long term downtrend reversing seem here. This swing trade heading to low 100's if it does. One of the best 2026 potential out there imo. 👀👀👀

1 · Reply

TheUnmaker Mar. 17 at 8:49 PM

0 · Reply

canievas Mar. 17 at 2:33 PM

$BCDA target here $50 and she will rest at $25 Buy Now before it’s to late. 🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀 Be patient

0 · Reply

chris_stocks Mar. 17 at 1:33 PM

0 · Reply

Jusme Mar. 17 at 1:05 PM

$BCDA FDA Helix approval coming soon!

0 · Reply

Denk333 Mar. 16 at 12:20 PM

$BCDA I will keep an eye on this one this week. It has been accumulating and flashing

0 · Reply

BOUDIN420 Mar. 14 at 12:02 AM

$BCDA expecting full results from phase 3 data in Q1 here...

2 · Reply

Raycloser Mar. 12 at 10:44 PM

$BCDA the fact that there’s been no dilution in a bit gives me hope (trying not to jinx it)

1 · Reply

BOUDIN420 Mar. 12 at 6:01 PM

$BCDA

0 · Reply

chris_stocks Mar. 12 at 9:41 AM

$BCDA Altman said the first and second quarters of 2026 will be transformative for the company. The first quarter is close to being over, but I'm not seeing anything that's what I'd call transformative yet. Maybe 2nd quarter will be better. As I understand it, the FDA takes a shorter time to come to a decision on a device than they do on a drug, so we should have news on that by June, I would think.

1 · Reply

Raycloser Mar. 9 at 4:02 PM

$BCDA does anyone have thoughts on if the cuorips approval will help us

1 · Reply

myrongoins Mar. 6 at 4:50 AM

$BCDA Slurped up a few hundo on this tasty dip The high BNP subgroup Echocardiography data is very important for a specific situation. Iykyk

1 · Reply

BillionerOfKing Mar. 4 at 10:51 PM

$BCDA Current Stock Price: $1.19

0 · Reply

chris_stocks Mar. 4 at 6:59 PM

$BCDA I'm honestly so sick of holding on to the stock. Come on b c d a move already!!!!

1 · Reply

FedericoC Mar. 4 at 9:40 AM

$BCDA The results of the CardiAMP HF trial were already known and provided the basis to initiate the CardiAMP HF II trial. Positive aspects already known on the target subgroup (patients with elevated NT-proBNP) are confirmed. Time horizon beyond 2026, but no reason to abandon this stock.

0 · Reply

Jusme Mar. 4 at 3:26 AM

$BCDA Added today, now holding 64,591 shares.

1 · Reply

TheSuper Mar. 4 at 2:01 AM

$BCDA -A results.... but market didnt react much. I think warrants at 1.25 were exercised as well... im out. For tilt into CING and SLS.

2 · Reply

Raycloser Mar. 3 at 3:50 PM

$BCDA is it the results or the market that’s the problem today

0 · Reply

Market Cap	13.05M
Revenue (ttm)	60,000.00
Net Income (ttm)	-7.95M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-13,250.00%
Debt to Equity Ratio	0.00

Volume	37,900
Avg Vol	71,198
Day's Range	N/A - N/A
Shares Out	10.61M
Stochastic %K	16%
Beta	0.60
Analysts	Sell
Price Target	$15.50